1228552-62-2

Basic information

• Product Name: (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;(S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(WX638029)
• CAS NO: 1228552-62-2
• Molecular Formula: C₁₂H₁₈IN₃O₂
• Molecular Weight: 363.19469
• Mol File: 1228552-62-2.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1228552-62-2)
• EPA Substance Registry System: (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1228552-62-2)

Safety Data

• Hazardous Substances Data: 1228552-62-2(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate is a chemical compound consisting of a pyrrolidine ring with a carboxylate ester function attached to it, along with an imidazole ring bearing an iodine atom. The compound is chiral, with the tert-butyl group contributing to its three-dimensional structure. This chemical may have potential applications in the synthesis of pharmaceuticals or other bioactive molecules, as the presence of the imidazole ring and iodine atom could confer specific reactivity or binding interactions. It may also be used as a reference standard or in research for understanding the reactivity and properties of similar chemical structures.

Upstream product

• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1228968-38-4 (S)-2-(4,5-Diiodo-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 147-85-3 L-proline 
• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 69610-41-9 Boc-L-Pro-H 

Downstream Products

• 1228968-39-5 C₁₉H₂₄IN₃O₄S 
• 1228968-86-2 (S)-tert-butyl 2-(5-((4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)ethynyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1307304-40-0 (S)-4-((2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)ethynyl)phenylboronic acid 
• 1307303-67-8 (2R,2'R)-1,1'-((2S,2'S)-2,2'-(5,5'-(buta-1,3-diyne-1,4-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(2-phenyl-2-(piperidin-1-yl)ethanone) 
• 1228966-45-7 methyl ((1S)-1-(((2S)-2-(4-(4'-((2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)ethynyl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate 
• 1228998-14-8 1,4-bis((2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)ethynyl)benzene 
• 1240893-37-1 methyl ((1S)-1-(((2S)-2-(4-((4-((2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)ethynyl)phenyl)ethynyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate 
• 1399845-04-5 ((S)-1-{(S)-2-[5-(4-Chloro-3-cyano-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1399845-03-4 {(2S,5S)-2-[5-(2'-Cyano-4'-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-4-oxo-1,2,4,5,6,7-hexahydro-azepino[3,2,1-hi]indol-5-yl}-carbamic acid methyl ester 
• 1613055-24-5 C₁₈H₃₀BN₃O₄ 
• 1613055-52-9 C₅₁H₆₈N₈O₆ 
• 1613055-16-5 C₄₅H₅₆N₈O₆ 
• 1613056-65-7 C₅₄H₆₆N₈O₇ 
• 1613055-14-3 C₄₁H₅₀N₆O₄ 

Relevant articles and documents

Compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and application of compounds or pharmaceutical composition

The invention discloses compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and an application of the compounds or the pharmaceutical composition. The compounds are compoundsshown in formula (I) or a stereoisomer, geometric isomer, a tautomer, an enantiomer, sulfur oxide, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compounds shown in formula (I); the compounds are effective antiviral drugs, especially can be used for inhibiting the function of NS5A protein encoded by the HCV, thereby effectively inhibiting the HCV.The method for preventing and/or treating drugs or diseases associated with the HCV by the compounds or the composition containing the new compounds has good market development prospects.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.